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Aims Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) in the Tafamidis in
Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). While ATTR-ACT was not designed for a dose-specific
assessment, further analysis from ATTR-ACT and its long-term extension study (LTE) can guide determination of the
optimal dose.
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Methods
and results
In ATTR-ACT, patients were randomized (2:1:2) to tafamidis 80 mg, 20 mg, or placebo for 30 months. Patients
completing ATTR-ACT could enrol in the LTE (with placebo-treated patients randomized to tafamidis 80 or
20 mg; 2:1) and all patients were subsequently switched to high-dose tafamidis. All-cause mortality was assessed
in ATTR-ACT combined with the LTE (median follow-up 51 months). In ATTR-ACT, the combination of all-cause
mortality and cardiovascular-related hospitalizations over 30 months was significantly reduced with tafamidis 80 mg
(P = 0.0030) and 20 mg (P = 0.0048) vs. placebo. All-cause mortality vs. placebo was reduced with tafamidis 80 mg
[Cox hazards model (95% confidence interval (CI): 0.690 (0.487–0.979), P = 0.0378] and 20 mg [0.715 (0.450–1.137),
P = 0.1564]. The mean (standard error) change in N-terminal pro-B-type natriuretic peptide from baseline to Month
30 was −1170.51 (587.31) (P = 0.0468) with tafamidis 80 vs. 20 mg. In ATTR-ACT combined with the LTE there
was a significantly greater survival benefit with tafamidis 80 vs. 20 mg [0.700 (0.501–0.979), P = 0.0374]. Incidence
of adverse events in both tafamidis doses were comparable to placebo.
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Conclusion Tafamidis, both 80 and 20 mg, effectively reduced mortality and cardiovascular-related hospitalizations in patients
with ATTR-CM. The longer-term survival data and the lack of dose-related safety concerns support tafamidis 80 mg
as the optimal dose.
Clinical Trial Registration: ClinicalTrials.gov NCT01994889; NCT02791230.
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Introduction
Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by
the accumulation of wild-type (ATTRwt) or variant (ATTRv)
transthyretin (TTR) amyloid fibrils in the myocardium, leading to
cardiomyopathy and symptoms of heart failure (HF).1 ATTRwt typ-
ically has a late symptom onset (>60 years of age) with the major-
ity of patients being male, while symptom onset in patients with
ATTRv may occur at younger ages.1,2 Specific TTR mutations, such
as Val122Ile, Thr60Ala, Leu111Met, Ile68Leu,3–6 are commonly
associated with ATTR-CM, but cardiomyopathy can occur with
other mutations. For example, Val30Met is generally associated
with polyneuropathy, but many patients also experience cardiac
findings, including cardiomyopathy.2,7–9
In this disease, dissociation of the tetrameric TTR into
monomers is followed by a rapid misfolding and misassem-
bling of the monomers into aggregates, with tetramer dissociation
being the rate-limiting step in TTR amyloid formation.10 Tafamidis
inhibits TTR dissociation into monomers by binding to the
thyroxine-binding sites, which stabilizes the tetramers, thereby
preventing fibril formation,11–13 and has been shown to slow the
progression of peripheral neurologic impairment in transthyretin
amyloid polyneuropathy (ATTR-PN).10
The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
(ATTR-ACT) demonstrated that tafamidis (compared with
placebo) improves survival, reduces cardiovascular (CV)-related
hospitalizations, and improves measures of function and
health-related quality of life (HRQoL) in patients with ATTR-CM.14
In ATTR-ACT, patients were randomized in a 2:1:2 ratio to
tafamidis 80 mg, tafamidis 20 mg, or placebo, and the primary
analysis compared the pooled tafamidis (80 and 20 mg) treated
group with the placebo group.14 ATTR-ACT was not designed to
assess the relative efficacy of each dose of tafamidis. The 80 mg
dose was included as it results in near maximal TTR stabilization10
and, together with the 20 mg dose, enabled the assessment of
adequately separated doses.15 Higher doses of tafamidis were
previously assessed in a randomized placebo-controlled study
in healthy subjects (n = 42), in which a single supra-therapeutic
dose of tafamidis (400 mg), with a maximum steady-state tafamidis
concentration approximately 7.5 times higher than with a clinical
dose of 20 mg, was generally well tolerated.16
Here we present the results of additional analyses of data from
ATTR-ACT and the long-term extension study (LTE), separately
comparing the safety and efficacy of the 80 and 20 mg doses of
tafamidis with placebo, in addition to changes in biomarkers and
survival data directly comparing the tafamidis 80 and 20 mg doses.
Methods
Study design and patients
The design of this phase 3, multicentre, international, three-arm,
parallel-design, placebo-controlled, double-blind, randomized study
(ATTR-ACT) has been published previously (NCT01994889).14,15
Briefly, patients were eligible to enrol if they met the following crite-
ria: (i) age ≥18 and ≤90 years with ATTR-CM defined by the presence



















































































.. HF with at least one prior hospitalization due to HF, or clinical evi-
dence of HF without hospitalization (volume overload or elevated
intracardiac pressures) that required treatment with a diuretic; (iii)
end-diastolic intraventricular septal wall thickness >12 mm demon-
strated by echocardiography; (iv) 6-min walk test (6MWT) of >100 m;
and (v) N-terminal pro-B-type natriuretic peptide (NT-proBNP) con-
centration ≥600 pg/mL. Exclusion criteria included: (i) prior treatment
with tafamidis; (ii) HF not due to ATTR-CM (based on the opinion of
the investigator); (iii) New York Heart Association (NYHA) class IV;
(iv) modified body mass index (BMI)<600 kg/m2⋅g/L (serum concentra-
tion of albumin multiplied by BMI); (v) estimated glomerular filtration
rate (eGFR) <25 mL/min/1.73 m2; (vi) prior liver or heart transplanta-
tion; and (vii) light chain amyloidosis.
All randomized patients who received at least one dose of study
drug were included in the safety analysis set and assessed for adverse
events. Patients with ATTR-CM were randomized in a 2:1:2 ratio to
receive tafamidis 80 mg, tafamidis 20 mg, or matching placebo once
daily for 30 months. Patients were stratified by TTR genotype (ATTRv
and ATTRwt) and NYHA baseline severity classification (NYHA class
I and NYHA classes II and III combined).
Upon completion of the 30-month double-blind study, patients
could enrol in the LTE (NCT02791230), in which patients could be
treated with tafamidis for up to an additional 60 months.15 In the LTE,
patients continued to receive the tafamidis dose to which they had
been randomized in ATTR-ACT. Patients who had received placebo
in ATTR-ACT were re-randomized to receive either 80 or 20 mg
tafamidis in the LTE [in a 2:1 ratio; stratified by TTR genotype (ATTRv
and ATTRwt)]. In ATTR-ACT and the LTE, a dose reduction could
be requested if patients experienced adverse events that may be
associated with poor tolerability. The only actual reduction possible
was for patients randomized to 80 mg. As of 20 July 2018, the LTE
protocol was amended to transition all patients to tafamidis free
acid 61 mg; a new, single capsule formulation bioequivalent to the
tafamidis meglumine 80 mg used in ATTR-ACT17 (graphical abstract).
The transition to tafamidis free acid 61 mg followed the protocol
amendment date, not a specified duration of treatment. As such,
patients were treated with tafamidis 80 or 20 mg during the LTE for
different durations prior to the protocol amendment. The median
duration of exposure to tafamidis prior to the transition to tafamidis
free acid 61 mg was 39 months in total (in ATTR-ACT and the LTE).
Both studies were approved by the independent review boards or
ethics committee at each participating site, and were conducted in
accordance with the provisions of the Declaration of Helsinki and
the International Conference on Harmonisation Good Clinical Practice
guidelines. All patients provided written informed consent.
Efficacy outcomes
The primary analysis in ATTR-ACT was a hierarchical combina-
tion of all-cause mortality (in which transplantation, either heart
or combined heart and liver, or implantation of cardiac mechanical
assist device were counted as death) and frequency of CV-related
hospitalizations for pooled tafamidis compared with placebo using the
Finkelstein–Schoenfeld method.14,15,18 Here, this analysis was con-
ducted separately for each tafamidis dose (80 and 20 mg) compared
with placebo. The key secondary endpoints were change from baseline
to Month 30 in the distance walked during the 6MWT19 and the Kansas
City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS)
score, based on a subset of the 23-item, patient-completed KCCQ that
assesses HRQoL.20 Additional secondary analyses included CV-related
mortality and TTR stabilization at Month 1. Exploratory endpoints
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included change from baseline to Month 30 in NT-proBNP and tro-
ponin I concentrations, and TTR stabilization and TTR concentration
throughout the study. The TTR stabilization assay was performed
using plasma samples (LabCorp, Los Angeles, CA, USA).10–12
All-cause mortality with tafamidis 80 mg compared with 20 mg was
assessed over a longer duration of treatment by combining data
from ATTR-ACT (median follow-up 30 months) with the LTE (median
follow-up 51 months). In addition to ATTR-ACT data alone, analyses
were conducted for ATTR-ACT combined with LTE patients, which
included the additional exposure to tafamidis free acid 61 mg after
patients transitioned to the new 61 mg formulation (as of 1 August
2019). Patients continued to be compared based on their initial dose
randomization (tafamidis 80 vs. 20 mg).
Statistical analyses
Unless stated otherwise, all analyses were carried out on the modified
intent-to-treat population of the randomized controlled study, which
included all randomized patients with at least one post-baseline efficacy
evaluation and who received at least one dose of study drug.
Details on the statistical analyses have previously been
published.14,15 Here, the two doses of tafamidis were compared
with placebo using the Finkelstein–Schoenfeld method,18 as applied in
the primary analysis. The Cox proportional hazards model was used
to analyse all-cause mortality. Poisson regression analysis was used
to analyse frequency of CV-related hospitalization. Secondary and
exploratory endpoints (NT-proBNP and troponin I) were evaluated at
each time point post-baseline using a mixed model repeated measures
ANCOVA (MMRM) with an unstructured covariance matrix (or as
appropriate), centre, and patients within centre as random effects. The
fixed effects were treatment, visit, TTR genotype (ATTRv vs. ATTRwt),
and visit by treatment interaction; and baseline score was used as a
covariate. For all MMRM analyses, there was no imputation of missing
values. The proportion of patients achieving TTR stabilization at
Month 1 was compared using the Cochran–Mantel–Haenszel test.
All-cause mortality in ATTR-ACT alone and combined with the LTE
was assessed as above, based on the pre-specified Cox proportional
hazards model with treatment, NYHA baseline classification, and
genotype in the model, and also separately adjusted for additional
covariates by adding age, NT-proBNP (log transformed), and 6MWT
distance as covariates to the pre-specified model (both individually and
all three combined). Time of initiation of tafamidis was used as time
zero in all survival analyses.
Results
Patient characteristics and transthyretin
stabilization in ATTR-ACT
Of the 548 patients screened for ATTR-ACT, 441 were random-
ized to receive tafamidis 80 or 20 mg or placebo (176, 88, and 177,
respectively), and 113, 60, and 85 patients, respectively, completed
the study. Survival status was collected for all 441 patients at Month
30. Demographic and clinical characteristics are shown in online
supplementary Table S1.
Transthyretin stabilization at Month 1 was achieved in a signifi-
cantly greater proportion of patients treated with tafamidis 80 and
20 mg [144/164 (87.8%) and 67/81 (82.7%) patients, respectively]



















































































.. Treatment with tafamidis 80 mg also resulted in a greater degree
of TTR tetramer stabilization than 20 mg (online supplementary
Figure S1A). Over the 30 months of the study, patients treated with
tafamidis 80 mg had higher mean TTR concentrations than those
treated with 20 mg or placebo, with tafamidis 20 mg also higher
than placebo (online supplementary Figure S1B).
Efficacy in ATTR-ACT
In ATTR-ACT, both tafamidis 80 and 20 mg significantly reduced
all-cause mortality and CV-related hospitalizations compared with
placebo (P = 0.0030 and P = 0.0048, respectively) (Table 1).
Tafamidis 80 and 20 mg also both significantly reduced the
decline in the 6MWT distance at Month 30 compared with placebo
[least squares (LS) mean (standard error, SE) metres, 75.77 (10.08)
and 75.57 (13.71), respectively; P< 0.0001 for both], with the
effect being observed from Month 6 (Figure 1A).
Similarly, the change from baseline to Month 30 in KCCQ-OS
score showed a reduction in decline in patients treated with both
tafamidis 80 and 20 mg compared with placebo [LS mean (SE),
13.48 (2.20) and 13.99 (2.96), respectively, P< 0.0001 for both]
(Figure 1B). The effect was observed from Month 6 with tafamidis
80 mg and from Month 12 with 20 mg (Figure 1B).
Treatment with tafamidis 80 mg significantly reduced all-cause
mortality vs. placebo [Cox proportional hazards model (95%
confidence interval, CI): 0.690 (0.487–0.979), P = 0.0378]. There
was a trend towards improvement with tafamidis 20 mg vs. placebo
[Cox proportional hazards model (95% CI): 0.715 (0.450–1.137),
P = 0.1564].
The frequency of CV-related hospitalizations was significantly
lower with both tafamidis 80 and 20 mg compared with placebo
(Table 1). There was a trend towards reduced CV-related mortality
with both doses of tafamidis compared with placebo [Cox propor-
tional hazards model (95% CI): 0.690 (0.470–1.012), P = 0.0579 for
tafamidis 80 mg; and 0.678 (0.404–1.139), P = 0.1421 for 20 mg].
Mortality in ATTR-ACT and combined
with the long-term extension study
Patients treated with tafamidis 80 mg in ATTR-ACT were sig-
nificantly older than those treated with 20 mg (median 76.0 vs.
73.5 years; P = 0.0405) and tended to have more severe disease as
assessed by NYHA classification, NT-proBNP, and 6MWT distance
(online supplementary Table S1). In ATTR-ACT there was a trend
towards a greater survival benefit with tafamidis 80 mg compared
with 20 mg, which was more pronounced (but not significant)
with adjustment by covariates (Figure 2). In the broader cohort
of ATTR-ACT combined with the LTE (including placebo-treated
patients in ATTR-ACT randomized to tafamidis), the differences
in disease severity between the tafamidis 80 and 20 mg groups
appeared to be less pronounced (online supplementary Table S2).
With the longer exposure of patients in ATTR-ACT combined
with the LTE (median follow-up 51 months), there was a significant
survival benefit with tafamidis 80 vs. 20 mg, with a 30% relative
reduction in the risk of death (P = 0.0374). The survival benefit
with tafamidis 80 mg compared with 20 mg was also significant
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Primary analysis with the Finkelstein–Schoenfeld method, all-cause mortality and frequency of
cardiovascular-related hospitalizations
Tafamidis
80 mg (n = 176)
Tafamidis
20 mg (n = 88)
Placebo
(n = 177)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary analysis
P-value from F-S method 0.0030 0.0048
Patientsa alive, n (%) 122 (69.3) 64 (72.7) 101 (57.1)
Average CV-related hospitalizations during 30 months
(PPPY) among those alive at Month 30
0.339 0.218 0.455
All-cause mortality, n (%) 54 (30.7) 24 (27.3) 76 (42.9)
Deaths 46 (26.1) 23 (26.1) 72 (40.7)
Heart transplants 6 (3.4) 1 (1.1) 4 (2.3)
Implantation of a CMAD 2 (1.1) 0 0
Patients with CV-related hospitalizations, n (%) 96 (54.5) 42 (47.7) 107 (60.5)
Frequency of CV-related hospitalizations per year 0.49 0.46 0.70
Tafamidis vs. placebo treatment difference, RRR (95% CI) 0.70 (0.57–0.85) 0.66 (0.51–0.86) –
P-value 0.0005 0.0017 –
CV-related events, n (%) 45 (25.6) 19 (21.6) 63 (35.6)
CV-related deaths 37 (21.0) 18 (20.5) 59 (33.3)
Heart transplants 6 (3.4) 1 (1.1) 4 (2.3)
Implantation of a CMAD 2 (1.1) 0 0
Tafamidis vs. placebo treatment difference, HR (95% CI) 0.69 (0.47–1.01) 0.68 (0.40–1.14) –
P-value 0.0579 0.1421 –
CI, confidence interval; CMAD, cardiac mechanical assist device; CV, cardiovascular; F-S, Finkelstein-Schoenfeld; HR, hazard ratio; PPPY, per patient per year; RRR, relative
risk ratio.
aPatients who discontinued due to heart or combined heart and liver transplantation, or due to implantation of a CMAD, were counted as death for this analysis.
(P< 0.05) with all covariate adjustments: 39% reduction in risk
of death with age adjustment; 36% with NT-proBNP adjustment;
30% with 6MWT distance adjustment; and 43% with adjustment
by all covariates combined (Figure 2).
Cardiac biomarkers in ATTR-ACT
The LS mean (SE) change from baseline to Month 30 in NT-proBNP
concentration for pooled tafamidis (80 and 20 mg doses together)
compared with placebo was −2180.54 (583.22) (P = 0.0002).
The increase in LS mean (SE) levels of NT-proBNP from baseline
to Month 30 (online supplementary Table S3) was significantly
reduced with tafamidis 80 mg compared with placebo [−2587.54
(570.25), P< 0.0001], while there was a trend towards a reduction
with tafamidis 20 mg compared with placebo [−1417.02 (743.38),
P = 0.0571]. Notably, while the increase in NT-proBNP at Month
30 was lower with each dose of tafamidis separately compared with
placebo, the increase with tafamidis 80 mg was also significantly
lower than with 20 mg [−1170.51 (587.31), P = 0.0468] (Figure 3A).
The LS mean (SE) change from baseline to Month 30 in troponin I
concentration for pooled tafamidis (80 and 20 mg doses together)
compared with placebo was −0.09 (0.023) (P = 0.0002). Similarly
to NT-proBNP, the increase in troponin I at Month 30 was lower
with each dose of tafamidis separately compared with placebo
[significantly for tafamidis 80 mg: −0.10 (0.018), P< 0.0001; but not
20 mg: −0.06 (0.045), P = 0.2246], with a lower (but not significant)
increase in troponin I with tafamidis 80 mg compared with 20 mg








































.. In a cumulative distribution of the percent change from baseline
in NT-proBNP concentration at Month 30, tafamidis 80 and 20 mg
both showed a consistent separation relative to placebo at a range
of thresholds for percent change from baseline (Figure 3C). There
was also a consistent separation with tafamidis 80 mg relative to
20 mg.
Safety and tolerability in ATTR-ACT
Both doses of tafamidis were generally well tolerated and had
a safety profile comparable to placebo (online supplemen-
tary Table S4). The proportion of patients who experienced
treatment-emergent adverse events (TEAEs) was similar across all
three groups, with the majority of TEAEs being mild or moderate
in severity. Dose reductions were infrequent, with two patients in
the tafamidis 80 mg group and four in the placebo group requesting
a dose reduction. Treatment-related TEAEs were reported by 79
(44.9%), 34 (38.6%), and 90 (50.8%) patients in the tafamidis 80 mg,
20 mg, and placebo groups, respectively, with diarrhoea being the
most common treatment-related TEAE with tafamidis 80 mg [14
(8.0%) patients], compared with two (2.3%) patients with 20 mg
and 18 (10.2%) patients with placebo. In the tafamidis 20 mg group,
urinary tract infection was the most common treatment-related
TEAE [5 (5.7%) patients] compared with four (2.3%) patients with
80 mg and eight (4.5%) patients with placebo.
A greater proportion of deaths was observed with placebo
[49 (27.8%), 23 (26.1%), and 72 (40.7%) patients for tafamidis
80 mg, 20 mg, and placebo, respectively]; the majority of all deaths
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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P < 0.0001P < 0.0001
P = 0.0273
Figure 1 Change from baseline with tafamidis 80 mg, tafamidis 20 mg, and placebo in (A) 6-min walk test (6MWT) distance and (B) Kansas
City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) in ATTR-ACT. P-values are for the treatment difference vs. placebo for
tafamidis 80 mg (shown above the curve) and tafamidis 20 mg (shown below the curve). LS, least squares; SE, standard error.
were considered to be a result of the disease [28 (57.1%), 17
(73.9%), and 49 (68.1%) for tafamidis 80 mg, 20 mg, and placebo,
respectively] and none were considered related to treatment with
tafamidis.
Safety and tolerability in ATTR-ACT
combined with the long-term extension
study
Safety in the LTE (up to an additional 12 months of treatment with
tafamidis, median follow-up of 36 months across both studies) com-
bined with ATTR-ACT was similar to the 30-month ATTR-ACT



















.. a prolonged treatment period. In the combined analysis, there were
227 and 115 patients evaluable for TEAEs with tafamidis 80 and
20 mg, respectively. The incidence of serious TEAEs was compa-
rable between tafamidis 80 and 20 mg (69.6% and 72.2%, respec-
tively), as was the incidence of severe TEAEs (53.3% and 53.0%,
respectively), and the proportion of patients who discontinued
treatment (17.6% and 20.0%, respectively). There were no patients
who reduced their dose due to TEAEs.
Discussion
In ATTR-ACT, tafamidis was shown to be an effective treatment
for ATTR-CM. Due to the limited number of patients who have
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Hazard ratio (95% CI)
0.700 (0.501–0.979)*
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Figure 2 Forest plot of covariate-adjusted all-cause mortality in ATTR-ACT and ATTR-ACT combined with the long-term extension study
(LTE). Hazard ratios are for: patients in ATTR-ACT (30 months follow-up), tafamidis 80 mg (n = 176) compared with 20 mg (n = 88); patients
in ATTR-ACT combined with the LTE and treatment with tafamidis free acid 61 mg (51 months follow-up), tafamidis 80 mg/tafamidis free acid
61 mg (n = 230) compared with tafamidis 20 mg/tafamidis free acid 61 mg (n = 116). The unadjusted row was based on the prespecified
Cox proportional hazards model with treatment, New York Heart Association baseline classification, and genotype in the model. The single
covariate-adjusted rows were generated by adding age, N-terminal pro-B-type natriuretic peptide (NT-proBNP) (log transformed), and 6-min
walk test (6MWT) distance separately as covariates to the pre-specified model. The all-covariate-adjusted row was generated by adding
all covariates to the pre-specified model. Patients who discontinued due to heart or combined heart and liver transplantation, or due to
implantation of a cardiac mechanical assist device, were counted as death for these analyses. *P-values for ATTR-ACT combined with the
LTE (51 months of follow-up) were: unadjusted, P = 0.0374; age-adjusted, P = 0.0054; NT-proBNP-adjusted, P = 0.0099; 6MWT-adjusted,
P = 0.0444; age/NT-proBNP/6MWT-adjusted, P = 0.0030. CI, confidence interval.
been diagnosed with this disease, ATTR-ACT was not designed to
assess the relative efficacy of each tafamidis dose. Further analysis
of the data from ATTR-ACT, together with interim data from its
LTE, provides guidance on the optimal dose of tafamidis in patients
with ATTR-CM. In this analysis, tafamidis was generally safe and
well tolerated, with a similar safety profile for the two doses of
tafamidis after 30 months of treatment and an extended period of
treatment, with a median of 36 months. Overall, there were fewer
dose reduction requests with tafamidis 80 mg than with placebo.
In ATTR-ACT, both doses of tafamidis (80 and 20 mg) effectively
reduced all-cause mortality and the frequency of CV-related hos-
pitalizations in patients with ATTR-CM. The decline in functional
capacity and HRQoL was significantly reduced with both doses
of tafamidis compared with placebo. While the reduction in the
decline in HRQoL compared with placebo was significant and first
observed at Month 6 with tafamidis 80 mg and from Month 12 with
20 mg, the efficacy of each dose of tafamidis was comparable. Over-
all, in ATTR-ACT mortality and CV-related hospitalizations were
comparable between the tafamidis doses.
In order to definitively assess the relative efficacy of each
dose, combining data from ATTR-ACT with the LTE provides
the opportunity for further comparison. With the longer dura-
tion of treatment, and the addition of patients previously treated
with placebo, a significant reduction in risk of death with tafamidis
80 mg compared with 20 mg was demonstrated (median follow-up
51 months). There was a significant difference between the doses,
with a 30% relative reduction in the risk of death with 80 mg com-
pared with 20 mg (P = 0.0374). These data were further supported











































. disease severity between the doses. As age is a prognostic factor for
survival, adjustment by age was included in the post-hoc analysis.
Given that the life expectancy of a 76-year-old male in the United
States is notably lower than that of a 73-year-old male (assuming an
exponential distribution and with the life expectancy of 10.58 years
for a 76-year-old and 12.43 years for a 73-year-old male21), there
is a 17.5% higher risk of death in the 76-year-old male. Similarly,
NT-proBNP and 6MWT distance are prognostic factors for sur-
vival in patients with ATTR-CM or HF.22–25 Adjustment by these
three covariates (age, NT-proBNP, and 6MWT) also resulted in a
significant difference between the doses.
Dose-dependent stabilization of TTR with tafamidis has previ-
ously been described in patients with ATTR-PN and in patients
with ATTR-CM, including patients with ATTRwt and patients with
a number of different TTR mutations.10–12 TTR stabilization was
maintained over the duration of those studies (up to 12 months).12
In ATTR-ACT, it was anticipated that the 80 mg dose of tafamidis
may result in a greater degree of TTR stabilization.15,26 While
both doses stabilized TTR in a significant proportion of patients,
only tafamidis 80 mg (and not 20 mg) approached the plateau
considered the target for stabilization (online supplementary
Figure S1A). There was also a higher mean TTR concentration with
tafamidis 80 mg, compared with 20 mg, suggesting that more TTR
was conserved in its tetramer structure and less dissociated TTR
was consumed in the amyloidogenic cascade.
Cardiac biomarkers such as NT-proBNP and troponin have pre-
viously been used alongside other biomarkers to assess disease
progression in patients with ATTR-CM.12,23,24,27 Higher base-
line levels of NT-proBNP (>3000 pg/mL) and reduced eGFR
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Least squares (LS) mean (standard error, SE) change in (A) N-terminal pro-B-type natriuretic peptide (NT-proBNP) and (B) troponin I
from baseline to Month 30 in ATTR-ACT. The differences from placebo at Month 30 in NT-proBNP and troponin I were significant for tafamidis
80 mg but not tafamidis 20 mg. (C) Cumulative distribution of percent change from baseline in NT-proBNP at Month 30 with tafamidis 80 mg,
tafamidis 20 mg, and placebo in ATTR-ACT.
(<45 mL/min) were significantly associated with increased mortal-
ity in patients with ATTR-CM.24 Higher baseline NT-proBNP and
troponin T levels were also significantly associated with increased
mortality in patients with ATTRwt.23 In ATTR-ACT, there was a
significant reduction in the increase in NT-proBNP and troponin
I over time with tafamidis 80 mg compared with placebo, and the
reduction in the increase in NT-proBNP with tafamidis 80 mg was
significantly greater than that with 20 mg. Furthermore, the per-
centage of patients with stable or reduced NT-proBNP levels at
Month 30 was higher with tafamidis 80 mg than 20 mg. NT-proBNP
was reduced in almost half (45.5%) of tafamidis 80 mg patients
[compared with one-quarter (23.3%) with 20 mg].
Limitations
As not all secondary and exploratory outcome measures were
collected in the LTE, it was not possible to assess the longer-term
effect of tafamidis treatment on cardiac biomarkers or measures of
































Tafamidis, at both 80 and 20 mg, effectively reduced mortal-
ity and CV-related hospitalizations, and the decline in func-
tional capacity and HRQoL in patients with ATTR-CM. While
ATTR-ACT was not designed to assess the relative efficacy of
each tafamidis dose, the lack of dose-related safety concerns,
together with TTR stabilization and NT-proBNP data, supported
the use of tafamidis 80 mg as the preferred dose. This was con-
firmed by longer-term (median 51 months) treatment data in which
there was a significant, 30% relative reduction in the risk of
death with tafamidis 80 mg compared with 20 mg. Taken together,
these data support the use of tafamidis 80 mg (bioequivalent to
tafamidis free acid 61 mg) as the optimal dose in patients with
ATTR-CM.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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